In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 61 for your search:

Drug:  therapeutic autologous dendritic cells
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase I/II Study of Immunization With In Vitro-Treated Autologous Tumor Cells and Dendritic Cells With Sargramostim (GM-CSF) in Patients With Stage III or IV or Recurrent Renal Cell Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: Other
Protocol IDs: HOAG-VACCINE-RN, NCI-V01-1647, NCT00014131

Vaccine Therapy in Treating Patients With Liver Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: CDR0000068806, P30CA016042, UCLA-0001026, NCI-G01-1997, NCT00022334

Phase I/II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides With or Without Ex Vivo CD40-Ligand Treatment in Patients With HLA-A1 and/or HLA-A2.1 Positive Stage III or IV Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: ERLANGEN-1490, EU-20232, NCT00053391

Phase I/II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides With or Without Ex Vivo CD40- Ligand and Denileukin Diftitox in Patients With HLA-A1- and/or HLA-A2.1-Positive Stage III or IV Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: over 18
Sponsor: Other
Protocol IDs: ERLANGEN-ONTAK, EU-20246, NCT00056134

Phase I/II Study of Vaccine Therapy Comprising Autologous Dendritic Cells Transfected With Autologous Polymerase Chain Reaction-Amplified Tumor RNA in Patients With Stage IV Cutaneous Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: ERLANGEN-DERMA-ER-DC-07, EU-20513, ARGOS-ERLANGEN-DERMA-DC-07, NCT00126685

Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AGS-003-004, Bukowski-8077, Logan-0506-05, Drabkin-05-0167, White-04-05-01A, Figlin-05-03-099-01, NCT00272649

Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: RDA 0466, NCT00289341

Combined Modality Treatment for Patients With Stage IV Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 21 to 75
Sponsor: Other
Protocol IDs: Baylor IRB #006-025-01, IND 12919, NCT00313235

Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: RDA-0537, NCT00345293

10.

Dendritic Cell Based Therapy of Renal Cell Carcinoma

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UR0414, NCT00197860

11.

Dendritic Cell Based Therapy of Malignant Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: MM0413, NCT00197912

12.

Daclizumab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia

Phase: Phase II, Phase I
Type: Diagnostic, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000579683, P50CA108786, P30CA014236, DUMC-PRO00000581, SPORE Project 3, Pro00000581, NCT00626483

13.

Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection

Phase: Phase II, Phase I
Type: Diagnostic, Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2004-3126, KUN99-1950, NCT00243594

14.

Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CRITICAL001, NCT00753220

15.

Preoperative Intratumor Dendritic Cells Injection Immunotherapy for Patients With Pancreatic Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 20 and over
Sponsor: Other
Protocol IDs: 198, NCT00795977

16.

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma

Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 19 months to 35 years
Sponsor: NCI
Protocol IDs: 070206, 07-C-0206, NCT00923351

17.

Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: NL22750.000.08, KUN2006-3699, NCT00940004

18.

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Over 16
Sponsor: Other
Protocol IDs: CDR0000068481, HOAG-VACCINE-MEL, NCI-V01-1646, NCT00012064

19.

A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas

Phase: Phase II
Type: Treatment
Status: Completed
Age: 35 and under at initial diagnosis
Sponsor: NCI
Protocol IDs: 970052, 97-C-0052, NCI-97-C-0052, NCI-T96-0038, T96-0038, NCT00019266, NCT00001566

20.

Phase II Randomized Study of CD34+ Derived or Peripheral Monocyte Derived Dendritic Cells Pulsed with MART-1 and gp100 Melanoma Antigens in Patients with High Risk Stage III or Completely Resected Metastatic Melanoma (Summary Last Modified 06/2002)

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-99-C-0132, NCT00019890

21.

p53 Vaccine for Ovarian Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 990137, 99-C-0137, NCI-99-C-0137, NCI-NMOB-9903, NCI-T99-0074, T99-0074, NCT00019903, NCT00001827

22.

Phase II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides From MART-1:26-35, gp100:209-217, and Tyrosinase:368-372 and Treated Ex Vivo With CD40-Ligand and Interferon Gamma, Followed By Interleukin-2 In Vivo in HLA-A2.1 Positive Patients With Stage III or IV Melanoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: LAC-USC-10M991, NCI-G00-1837, NCI-T99-0102, NCT00006113, T99-0102

23.

Phase II Study of APC8015 (Provenge) and Bevacizumab in Patients With Progressive Prostate Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: UCSF-0155-01, NCI-2617, UCSF-01554, NCT00027599, 2617

24.

DC Vaccine Combined With IL-2 and IFNa-2a in Treating Patients With mRCC

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000370794, R01CA095648, P30CA023108, DMS-0238, DMS-16090, NCT00085436

25.

Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally